Contract research and manufacturing company Syngene International has had a fabulous run this year. Its stock price has risen over 40% since January amid robust growth and a positive outlook for the business. Syngene’s market capitalisation has reached INR33,000 crore, surpassing the INR32,600 crore market cap of its parent company Biocon. Since its listing in 2015, the Syngene stock has been rising steadily. Its market cap touched INR20,000
Related Posts
How this Advent PE-backed Indian firm is prepping to take on Chinese big pharma
Illustration by Sadhana Saxena via AI. Synopsis Advent, which merged Suven Pharma with Cohance Lifesciences in February, looks to take advantage of the China+1 wave and other geopolitical tailwinds. While the skills of its scientists give India an edge in pharma outsourcing, the scale of local contract manufacturers pales in front of global rivals from […]
Dilip Jose: Manipal Health has set its sights on the top spot. Can it get there amid the intense competition?
Dilip Jose, Managing Director and CEO at Manipal Hospitals Synopsis Of late, Manipal Health has been focusing on getting bigger and improving operational efficiencies. With an aggressive and execution-oriented management and backing of marquee investors, it has expanded rapidly via the acquisitions route. However, with key rival Apollo Hospitals also increasing bed count across regions, […]
Sarah McMullen, the US FDA exec who soothed Indian pharma’s frayed nerves
Sarah McMullen, USFDA India director Synopsis In the past, many within the Indian pharma industry looked at US FDA audits as motivated and a larger conspiracy against it. But Sarah McMullen, who heads the Indian operations of the US FDA, worked hard to slowly change that, and bring in a culture of quality in the […]
